<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> worldwide, increasing in incidence with the aging population </plain></SENT>
<SENT sid="1" pm="."><plain>Substantial morbidity and mortality accompany its diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>Management should focus on rate and rhythm management, on reducing thromboembolic risk, and also potentially on targeting the mechanisms responsible for its perpetuation </plain></SENT>
<SENT sid="3" pm="."><plain>Current antiarrhythmic therapy has only modest efficacy and substantial side effects, and anticoagulation regimes are cumbersome and require regular monitoring </plain></SENT>
<SENT sid="4" pm="."><plain>Novel <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> and antiarrhythmics hold the promise of improved efficacy and safety </plain></SENT>
<SENT sid="5" pm="."><plain>This review covers current therapy for AF, major advances in pharmacological management and future directions for therapy </plain></SENT>
</text></document>